Nov 12,2021:Data from Phase 3 trials show the vaccine offers 78 percent protection against COVID-19, according to findings published in Lancet.
Covaxin, the first COVID-19 vaccine developed in India, is “highly efficacious” and presents no safety concerns, according to a study published in the medical journal Lancet.
Covaxin gained emergency approval from the World Health Organization last week, the eighth jab to be given the green light by the health body. The vaccine has already been cleared for use in 17 countries.
